Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
Sponsor: Duke University
Summary
This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating Scale, Revised (ALSFRS-R) progression.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-07-01
Completion Date
2026-08-01
Last Updated
2026-05-15
Healthy Volunteers
No
Conditions
Interventions
β-hydroxy-β-methylbutyrate (HMB)
Our source of HMB will be Life Extension's "Wellness Code Muscle Strength \& Restore Formula. The dose will be 3g daily, which has previously been shown to be safe and well-tolerated, and to reduce IGFBP7 blood levels in humans.
Locations (2)
Duke University Medical Center
Durham, North Carolina, United States
Temple University
Philadelphia, Pennsylvania, United States